AbbVie, Lilly Atopic Dermatitis Treatments Hit With Further Delays With FDA

AbbVie Inc (NYSE: ABBV) and Eli Lilly And Co (NYSE: LLY) will have to keep waiting for a chance for their JAK inhibitors in atopic dermatitis to see the market.

The companies separately said on Friday that the FDA again delayed decisions over their applications for Rinvoq (upadacitinib) and Olumiant (baricitinib) in moderate to severe atopic dermatitis.